463 Studies Now Enrolling
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Study of Drug that May Reduce Risk of Blood Clot Development in Cancer Patients Who Are Able to Walk
| Sponsor: | Janssen |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR5566 |
| U.S. Govt. ID: | NCT02555878 |
| Contact: | David Diuguid MD: 212-305-0527 / dld6@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to see if rivaroxaban is useful in reducing the risk of patients developing blood clots while undergoing cancer treatment. The safety of rivaroxaban will also be studied. Cancer diagnoses include: pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal, or lymphoma.
This study is closed
Do You Qualify?
| Are you 18 years or older? | Yes | No |
| Have you been diagnosed with solid tumor (inc. pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal, lymphoma)? | Yes | No |
| Are you able to walk, care for yourself, and do light physical activities like light housework or office work? | Yes | No |